Announcement on Subsidiary Company Obtaining Drug Registration Certificate
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2020-023
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Registration Certificate
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
Important Content Note:
- Obtaining the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical is qualified to produce and sell the drug, which will further enrich Jianfeng Pharmaceutical's product line and help enhance the competitiveness of the company's pharmaceutical business.
- Risk Warning: Because pharmaceutical products have the characteristics of high technology, high risk, and high added value, not only the pre-research and development of drugs, the period from approval to production is long, the investment is large, and there are many links, and the drug has obtained the registration The production and sales after the certificate are also easily affected by factors such as national policies and market environment. Investors are requested to pay attention to investment risks.
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the Drug Registration Certificate of esomeprazole sodium for injection (Certificate No.: 2020S00572) approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of
1. Drugs
Drug Name: Esomeprazole Sodium for Injection
Dosage Form: Injection
Specification: 40mg (calculated by C 17 H 19 N 3 O 3 S)
Application Items: drug Registration (Domestic Production)
Registration Classification: Original Chemical Drug Category 6
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
acceptance number: CYHS1301863 Zhejiang
Certificate No.: 2020S00572
Drug Registration Standard No.: YBH03162020
Drug Validity Period: 12 Months
Drug Approval Number: the validity period of the drug approval document number of the national drug standard H20203449
is until August 25, 2025
approval conclusion: according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements for drug registration, is approved for registration, and a drug registration certificate is issued. The production process, quality standards, instructions and labels shall be in accordance with the attached.
2. Drug Development and Related Conditions
This product is used to treat:
1. as an alternative therapy for GERD when oral therapy is not applicable.
2. Use in low-risk patients with acute gastric or duodenal ulcer bleeding for whom oral therapy is not applicable (gastroscopic Forrest grading IIc-III).
Esomeprazole sodium for injection has been listed in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition)" and classified as Class B; it is not included in the "National Essential Drugs List (2018 Edition)". At present, 30 enterprises, including AstraZeneca Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., and Shandong Luoxin Pharmaceutical Group Co., Ltd., have been approved for listing in China. According to the data of the intranet, the domestic sales in 2019 (including urban and county-level public hospitals, community and township health centers) are about 3.317 billion yuan.
Peak Pharmaceutical submitted an application for registration of the drug to the State Food and Drug Administration on November 28, 2013 and was accepted. Up to now, the research and development investment of esomeprazole sodium for injection project of Jianfeng Pharmaceutical Co., Ltd. is about 14.9128 million yuan. The impact of
3. on the company and its risks suggest that
Jianfeng Pharmaceutical already has a corresponding production line. The acquisition of the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug, which will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business. Due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the period from the preliminary research and development, approval to production is long, the investment is large and there are many links, but also the production and sales of drugs after obtaining the registration certificate are easily affected by national policies, market environment and other factors. Please pay attention to the investment risk.
This is to announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
September 5, 2020
More information
On January 4, the Jinhua Federation of Industry and Commerce held the sixth member congress. Jiang Xiaomeng, chairman of the group company, was elected as the chairman of the Jinhua Federation of Industry and Commerce at the meeting, and served as 20 "2016 Xinyi Good Wu Merchants" One of the commendations from relevant departments. Jinhua city leaders Zhao Guangjun, and military and civilian, Huang Jinchao, Chen Xiao, Shao Guoqiang, Xu Zhangcai attended the opening ceremony of the conference. Zhao Guangjun, Secretary of the municipal Party committee, congratulated the convening of the conference on behalf of the four groups of the city. He hoped that the Federation of industry and Commerce at all levels and the majority of non-public economic personages would unify their thoughts and actions to the deployment requirements of the plenary session of the municipal Party committee, further strengthen their confidence, grasp the general trend, forge ahead, always maintain the correct political direction, firmly promote the development of non-public economy, and make greater contributions to the rise of Zhejiang. At this meeting, Jiang Xiaomeng, chairman of the group company, was elected as the new chairman of the Jinhua City Federation of Industry and Commerce. Jiang Xiaomeng said in his speech that the Federation of Industry and Commerce is a bridge and link between the party and the government to connect with people in the non-public economy, an assistant to the government in managing and serving the non-public economy, and an important window for the interests of the broad non-public economy. it represents the fundamental interests of the broad non-public economy. In the next five years, the new Federation of Industry and Commerce will continue to enhance cohesion and influence based on service; give full play to the role of "guidance" and "bridge", and always maintain sensitivity to the new situation with advanced awareness and long-term vision, and pay close attention to domestic and foreign Industrial development trends and economic development trends, timely discover new situations, study new problems, and act as a bridge between the government and enterprises
2020
07-31
Compilation of Three-year Operation Plan Completed
After many discussions and revisions, the three-year business plan compiled by the group's subordinate enterprises was finalized in early December and compiled into a book. In order to continuously improve the company's core competitiveness and sustainable development capabilities, the group company completed the company's five-year development plan in 2013 after many discussions, and clarified the development concept of "cooperative innovation to strengthen the main business, standardize science and seek development", Put forward the role of cement as a base player and be a cost leader in the regional market; medicine is guided by scientific and technological innovation and a market leader in segmented fields. And on this basis, the specific strategic objectives and development direction are formulated. In the second half of this year, on the basis of the pilot medium-and long-term economic responsibility system of the International Trade Company and Jinhua Pharmaceutical Company, the company requires each industrial sector to prepare its own three-year business plan. This is not only one of the actions to implement the strategic plan of the group company, but also an extension of the development strategy of the group company. After full discussion and revision, the current three-year business plan has been compiled into a book, which will become the work guide for the company's professional companies and directly affiliated enterprises in the future. The preparation of medium and long-term development plans, so that the company's managers at all levels more clear about the future direction of development, to be able to develop work objectives and work plans with a long-term vision, to avoid short-sighted behavior in management, the work of the enterprise to do fine, solid, detailed, and at the same time more fully and effectively mobilize the enthusiasm of personnel at all levels. The company requires subordinate enterprises to do a good job in the publicity and implementation of the "three-year business plan" of the enterprise, and in the annual work objectives
2020
07-31
Compilation of Three-year Operation Plan Completed
After many discussions and revisions, the three-year business plan compiled by the group's subordinate enterprises was finalized in early December and compiled into a book. In order to continuously improve the company's core competitiveness and sustainable development capabilities, the group company completed the company's five-year development plan in 2013 after many discussions, and clarified the development concept of "cooperative innovation to strengthen the main business, standardize science and seek development", Put forward the role of cement as a base player and be a cost leader in the regional market; medicine is guided by scientific and technological innovation and a market leader in segmented fields. And on this basis, the specific strategic objectives and development direction are formulated. In the second half of this year, on the basis of the pilot medium-and long-term economic responsibility system of the International Trade Company and Jinhua Pharmaceutical Company, the company requires each industrial sector to prepare its own three-year business plan. This is not only one of the actions to implement the strategic plan of the group company, but also an extension of the development strategy of the group company. After full discussion and revision, the current three-year business plan has been compiled into a book, which will become the work guide for the company's professional companies and directly affiliated enterprises in the future. The preparation of medium and long-term development plans, so that the company's managers at all levels more clear about the future direction of development, to be able to develop work objectives and work plans with a long-term vision, to avoid short-sighted behavior in management, the work of the enterprise to do fine, solid, detailed, and at the same time more fully and effectively mobilize the enthusiasm of personnel at all levels. The company requires subordinate enterprises to do a good job in the publicity and implementation of the "three-year business plan" of the enterprise, and in the annual work objectives
2020
07-31
Since the beginning of the 2016 qualification evaluation work of the group company in late November, it has been carried out in an orderly manner according to the established procedures. Compared with previous years, this year, according to the actual situation of the company, new cement plate job settings and development channels and other content. According to the provisions of the Company's Measures for the Administration of Staff Qualifications, the scope of application of the qualification assessment is for all employees of the Group's non-administrative position series, which is divided into three categories: management, technology and technical operation. Among them, the management and technical categories are divided into five grades, each with 2-4 grades; the mechanic operation category is divided into four grades, each with 2-4 grades. The Group Company establishes a qualification evaluation committee, which is responsible for guiding the evaluation of the qualifications of the Group Company, and conducting the evaluation of the qualifications of each department (office) of the Group Company and the qualifications of four levels and above within the scope of the Group Company; professional companies and directly affiliated enterprises establish an evaluation organization, which is responsible for the evaluation of the qualifications of the enterprise and subordinate enterprises at level 3 and below; the Human Resources Department of CNPC is responsible for organizing the review work and carrying out the transactional work of qualification management. Compared with previous years, the company has made a supplementary revision to the "Measures for the Administration of Employee Qualifications" this year, adding a "cement sector position setting and development channel", aiming at the actual situation and professional characteristics of the current two cement companies implementing job optimization, positions such as safety and environmental protection management, sales management, procurement, warehouse management, quality management, equipment maintenance (management), electrical maintenance (management), process operation, inspection workers, etc. are set up respectively, and different levels are divided, and corresponding evaluation standards are set. In accordance with the Management Measures, the post
2020
07-31
Compilation of Three-year Operation Plan Completed
After many discussions and revisions, the three-year business plan compiled by the group's subordinate enterprises was finalized in early December and compiled into a book. In order to continuously improve the company's core competitiveness and sustainable development capabilities, the group company completed the company's five-year development plan in 2013 after many discussions, and clarified the development concept of "cooperative innovation to strengthen the main business, standardize science and seek development", Put forward the role of cement as a base player and be a cost leader in the regional market; medicine is guided by scientific and technological innovation and a market leader in segmented fields. And on this basis, the specific strategic objectives and development direction are formulated. In the second half of this year, on the basis of the pilot medium-and long-term economic responsibility system of the International Trade Company and Jinhua Pharmaceutical Company, the company requires each industrial sector to prepare its own three-year business plan. This is not only one of the actions to implement the strategic plan of the group company, but also an extension of the development strategy of the group company. After full discussion and revision, the current three-year business plan has been compiled into a book, which will become the work guide for the company's professional companies and directly affiliated enterprises in the future. The preparation of medium and long-term development plans, so that the company's managers at all levels more clear about the future direction of development, to be able to develop work objectives and work plans with a long-term vision, to avoid short-sighted behavior in management, the work of the enterprise to do fine, solid, detailed, and at the same time more fully and effectively mobilize the enthusiasm of personnel at all levels. The company requires subordinate enterprises to do a good job in the publicity and implementation of the "three-year business plan" of the enterprise, and in the annual work objectives
2020
07-30
"Peak" was identified as China's well-known trademark
Recently, the Trademark Office of the State Administration for Industry and Commerce issued a document that the "Jianfeng" trademark held by Jianfeng Pharmaceutical Company was recognized as a well-known trademark. The main contents of the "Reply of the Trademark Office of the State Administration for Industry and Commerce on the Identification of" Jianfeng "Trademark as a Well-known Trademark" (Shang Standard Chi Zi [2016] No. 121) are as follows: according to the relevant provisions of the Trademark Law, the regulations for the implementation of the Trademark Law and the provisions on the identification and protection of well-known trademarks, after examination and research, it is recognized that the registered trademark of "Jianfeng" used by Zhejiang Jianfeng Pharmaceutical Co., Ltd. in category 5 of the International Classification of Goods and Services for Trademark Registration is a well-known trademark. The identification of the well-known trademark has effectively enhanced the brand value of the company, helped to improve the popularity of the company's products, and further strengthened the protection of the "peak" trademark. (Zhou Hengbin) News link: "well-known trademark" (Well-knownTradeMark), also known as well-known trademark, first appeared in the Paris Convention for the Protection of Industrial property signed in 1883. According to international and domestic intellectual property laws and regulations, the well-known trademark system is created to fully protect the legitimate rights and interests of well-known trademark owners. Its purpose is to reasonably protect the relevant trademark ownership, maintain fair competition, and stop infringement of others' trademark exclusive rights. behavior. China joined the Convention in 1984, according to the provisions of the Convention to give special legal protection to well-known trademarks, has become an important part of China's trademark legal work. Well-known trademarks in China (ChinaFam
2020
07-31